Berntorp E. Stigendal L. Lethagen S. Olofsson L. Hedner U., NovoSeven in warfarin-treated patients. Blood Coagulation & Fibrinolysis. 11 Suppl 1:S113-5, 2000.
Hemorrhage represents a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect on the increased International Normalized Ratio value is vital to achieve hemostasis. As conventional treatment, that is plasma or plasma-derived concentrates, carries the risk of blood-borne virus transmission, new treatments are needed. An open, multicenter pilot trial is currently under way to determine the effect of recombinant activated factor VII (rFVIIa; NovoSeven) administered to patients experiencing a bleeding episode after receiving vitamin K antagonists. When rFVIIa was given to a patient with a warfarin-induced nosebleed, it had an immediate hemostatic effect and the International Normalized Ratio value virtually normalized.